Search

Memorial Sloan Kettering Cancer Center has filed an application with the New York State Department of Health to open a freestanding outpatient facility in Harrison, New York. If approved, the new 114,000-square-foot treatment facility will offer area residents the most advanced cancer care services, closer to home.

Despite the promise of eventually using artificial intelligence to detect melanoma, much more research and development are needed, MSK experts find.

Cancer DNA taken from spinal fluid could serve as a liquid biopsy that provides information on brain tumor mutations.

The $50 million donation from Mike and Maria Repole and the Nonna’s Garden Foundation will support cancer care on Long Island and significantly advance research efforts.

The Thrivers event at Memorial Sloan Kettering celebrates Bone Marrow Transplant recipients on their return to health.

Selpercatinib (also known as LOXO-292) is a highly selective RET inhibitor with activity against diverse RET fusions, activating RET mutations and brain metastasis. Phase 1/2 data from the LIBRETTO-001 trial presented at the IASLC 2019 World Conference on Lung Cancer demonstrates selpercatinib’s marked antitumor activity in RET fusion-position non-small cell lung cancer (NSCLC) patients. These findings, presented by Alexander Drilon, MD, principal investigator and Research Director of Early Drug Development at Memorial Sloan Kettering Cancer Center, will form the basis of an US Food and Drug Administration new drug application submission.

The Gene: An Intimate History is a new four-hour documentary from the award-winning Ken Burns team and PBS, adapted from the award-winning book of the same name by Siddhartha Mukherjee, MD, DPhil. Memorial Sloan Kettering’s Luis Alberto Diaz, Jr., MD, Head of the Division of Solid Tumor Oncology, is a featured expert.

All radiotherapy treatments for prostate cancer should be accompanied by image-guidance of the prostate position to rule out significant setup errors in fractional delivery.